Drugs / Neihulizumab
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04144036 | Dec 2020 → Apr 2023 | acute graft versus host disease | Sameem M. Abedin, MD | Completed | No outcome recorded |
| Phase 1 | NCT03327857 | May 2018 → Sep 2022 | acute graft versus host disease | AltruBio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02436460 | May 2015 → Mar 2016 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Terminated | No outcome recorded |
| Phase 1 | NCT01378364 | Jun → Nov 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00848055 | Dec 2008 → Oct 2010 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03298022 | May 2018 → Apr 2020 | ulcerative colitis | AltruBio Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02694770 | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
| Phase 2 | NCT02267642 | Jan → Oct 2015 | psoriatic arthritis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
| Phase 2 | NCT02223039 | May → Dec 2014 | psoriasis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
| Phase 2 | NCT01855880 | May 2013 → Feb 2014 | psoriasis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neihulizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144036 ↗ |
| Known as | AbGn-168H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01855880 ↗ |
| Known as | AbGn168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00848055 ↗ |
| Known as | ALTB-168 | “Neihulizumab (ALTB-168) is an immune checkpoint agonist antibody that regulates T cell homeostasis.” NCT03327857 ↗ |
| Action | Deplete | “induces cell death preferentially in late-stage activated T cells” NCT03327857 ↗ |
| Action | Inhibit | “P-selectin glycoprotein ligand 1 inhibitor” CHEMBL4297861 ↗ |
| Modality | Monoclonal antibody | “AbGn-168H monoclonal antibody” NCT02223039 ↗ |
| Route | Intravenous | “single dose intravenous infusion” NCT00848055 ↗ |
| Target | SELPLG | “P-selectin glycoprotein ligand 1 inhibitor” CHEMBL4297861 ↗ |